Canada: Canadian Court Overturns Decision on International Pharmaceutical Transfer Pricing Case

Last Updated: September 2 2010
Article by John Tobin

The Canadian Federal Court of Appeal recently overturned the Tax Court of Canada's 2008 decision regarding the international transfer pricing of cross-border supplies of pharmaceutical ingredients in the case of GlaxoSmithKline Inc. v. Canada. At issue was the price GlaxoSmithKline (Glaxo Canada) paid to a related non-resident supplier for the drug ranitidine, the active pharmaceutical ingredient in the stomach ulcer drug Zantac. The Tax Court had accepted the Canada Revenue Agency's position that Glaxo Canada had paid an unreasonable amount for the ranitidine, thereby adding some $51 million to Glaxo Canada's income for the years in question.

Background

Under a supply agreement with the supplier for the purchase of ranitidine, Glaxo Canada had paid between $1,512 and $1,651 per kilogram between 1990 and 1993. The Tax Court found that generic drug companies had paid between $194 and $304 per kilogram during the same period for substantially the same drug (although not produced in Glaxo Canada's own facilities). Separately, Glaxo Canada had entered into a licence agreement with its parent company, Glaxo Group Limited. The licence agreement provided for the right to use the parent's trademarks and patents, including the right to market ranitidine under the Zantac brand, as well as provide access to a portfolio of other drugs. Glaxo Canada agreed to pay Glaxo Group a 6% royalty on net sales of Zantac and other drugs.

The Tax Court Decision

At trial, the Tax Court considered the application of former subsection 69(2) of the Income Tax Act, which provided that the deductibility of amounts paid to a nonresident related party is limited to an amount that would have been "reasonable in the circumstances." The trial judge relied on the Supreme Court of Canada's decision in Singleton v. Canada and held that the licence agreement was not to be considered when determining the reasonableness of the price paid under the supply agreement because the two agreements covered separate matters. Using this approach, the trial judge used the prices that generic drug companies paid for their purchases of ranitidine as comparables and ruled that the reasonable price for Glaxo Canada to pay the supplier was the highest price paid by the generics for their supply of ranitidine plus a small adjustment.

The Federal Court of Appeal Decision

On appeal, the Federal Court of Appeal (FCA) overturned the Tax Court's decision regarding the relevance of the licence agreement. It found that the trial judge had erred in law by failing to apply the proper test and had erroneously equated "fair market price" with the "reasonable in the circumstances" test set out in Gabco Limited v. MNR. The FCA held that what is reasonable in the circumstances "requires an inquiry into those circumstances which an arm's length purchaser, standing in the shoes of [Glaxo Canada], would consider relevant" in deciding a reasonable amount to pay for ranitidine.

The FCA identified five circumstances that made the licence agreement a crucial factor in determining the amount that would have been "reasonable in the circumstances" if Glaxo Canada and the supplier had been in an arm's-length relationship:

  1. Glaxo Group owned the Zantac trademark and would own it even if Glaxo Canada was arm's length.
  2. Zantac (sold under that brand name) commanded a premium in the marketplace over generic ranitidine drugs.
  3. Glaxo Group owned the ranitidine patent and would have owned it even if Glaxo Canada had been in an arm's-length relationship.
  4. Without the licence agreement, Glaxo Canada would not have been a position to use the Zantac trademark or the ranitidine patent. Therefore, the only other possibility available to Glaxo Canada would have been to enter the generic market, where the barriers to entry would have been high, with established companies already well-positioned.
  5. Without the licence agreement, Glaxo Canada would not have had access to Glaxo Group's portfolio of other patented and trademarked products.

The FCA made an important finding for transfer pricing cases. It noted that the particular circumstances of the case arose through Glaxo Group's ownership of specific intellectual property rights associated with the drug, which were granted to Glaxo Canada, and not from the non-arm's-length relationship between Glaxo Canada and the supplier or Glaxo Group. However, the FCA chose not to render a decision on the appropriate amount of the transfer price. Instead, the matter was sent back to the Tax Court for redetermination with instructions to consider the full "business realities" of the case.

Further Considerations

The FCA did not discuss the reasonableness of the amounts paid under the licence agreement and avoided the question of the appropriate allocation to each agreement. It merely stated that the licence agreement is a circumstance that the Tax Court must take into account. The Tax Court's ultimate valuation determination will likely be unable to consider whether the amounts paid under the licence agreement were reasonable in the circumstances because the prices paid under the licence agreement were not in issue before the courts. The only issue raised by Canada Revenue Agency on assessment was whether the payments for ranitidine were too much in the circumstances (i.e., given the royalty rate already set out in the licence agreement). In view of the existing licence agreement, it may well be that Glaxo Canada paid a reasonable price for ranitidine.

The argument made by counsel in the FCA case was intuitively attractive: a reasonable person would pay more to get ranitidine that it can sell as "Zantac" because it expects to get a premium price for its product; however, it is not clear that this argument holds up when the entire relationship is viewed together. Is the price for ranitidine high and therefore justifiable because the royalty rate is low? Or if the royalty rate was "on market," was the price for ranitidine too high?

It may be that, taken as a whole, the combined purchase price for the royalty plus the raw drug is reasonable in the circumstances, but having chosen to split the two agreements among two counterparties, the taxpayer faces the difficult situation of having one part unchallenged and the other reduced.

The FCA decision does not give much guidance to the Tax Court. Given the licence agreement, the Tax Court will find it exceedingly difficult to find an appropriate comparable or to apply normal transfer pricing methodologies. There is unlikely to be a comparable in which an arm's-length party has the rights at a specific level of royalty to market a given product and then buy the raw material from a third party.

In the end, the Federal Court of Appeal has taken the much broader view, consistent with that held by most taxpayers, that the proper approach in assessing transfer pricing disputes is to take into account the full extent of the business and market realities pertaining to the situation. What remains to be seen is how the Tax Court will tackle the difficulties inherent in establishing an appropriate transfer price without guidance on the methodology to adopt or specific instructions on how to deal with the challenges of finding an appropriate arm's-length comparable when there are several contracts (with associated pricing) between several counterparties.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.